Printer Friendly

Carotid Intima-Media Thickness and Visit-to-Visit HbA1c Variability Predict Progression of Chronic Kidney Disease in Type 2 Diabetic Patients with Preserved Kidney Function.

1. Introduction

Chronic kidney disease (CKD) has been consistently and independently associated with longitudinal risk for cardiovascular disease and heart failure. Progression towards endstage renal disease exposes CKD patients to an increased risk of development of vascular disease and cardiovascular morbidity and mortality [1, 2]. Established cardiovascular disease risk factors (diabetes and hypertension) are associated with the development of new-onset kidney disease [3]. Other cardiovascular disease risk factors, such as cigarette smoking, inflammation, and dyslipidemia, have also been linked to declining kidney function in some, but not all, studies [4-8].

These overlapping risk factor patterns lead us to hypothesize that atherosclerosis may be an important mechanism leading to declines in kidney function. Prospective studies have shown a positive correlation between increased carotid artery intima-media thickness (IMT), a subclinical marker of atherosclerosis and cardiovascular disease, and the risk for kidney function decline and incident CKD in the elderly [9, 10]. In addition, carotid IMT was associated with incident CKD in the general population [11]. However, there is limited understanding of whether the presence of a subclinical marker of atherosclerosis, like carotid IMT, is an important predictor for progression to CKD in type 2 diabetic patients. We hypothesized that, among patients with type 2 diabetes and normal or near-normal kidney function at the initiation of the observation period, the baseline IMT would be associated with the deterioration of CKD over time. We have recently shown a direct association between visit-to-visit HbA1c variability and kidney function decline in patients with type 2 diabetes [12]. Hence, we examined in the present study an association between visit-to-visit HbA1c variability and deterioration of CKD as well.

2. Patients and Methods

The setting for this observational study was the same as previously reported [12]. We report here results of 162 patients in whom carotid IMT was measured during the first 12 months after enrollment. They had been regularly attending the clinic in 2004 and 2005. They were enrolled in the study at the first visit in 2005 and followed up for the subsequent at least 24 months through December 31,2012, to assess kidney function with a median follow-up of 6.0 years (interquartile range: 4.1-6.5 years). There were 14 patients who had been regularly attending the clinic in 2004 and 2005 and did not follow up for the subsequent 24 months. One patient died of a traffic accident, 6 moved, and 3 patients stopped visiting because of their job situations. The reason was not known in the remaining 4 patients. There were no differences between the 14 patients and 162 patients studied in anthropometric, clinical, and biochemical variables (data not shown). Patients with hepatitis B surface antigen or antibodies against hepatitis C virus were excluded. Those who had aspartate aminotransferase and alanine aminotransferase of 100 U/L or greater and serum creatinine [greater than or equal to] 2.0 mg/dL were excluded as well. Study protocol was consistent with the Japanese Government's Ethical Guidelines Regarding Epidemiological Studies in accordance with the Declaration of Helsinki.

For each subject on each monthly visit, waist circumference, weight, and BP were measured by registered nurses. As previously reported in detail [12], blood was withdrawn on 2 occasions: at 2 h after breakfast taken at home and after an overnight fasting in the majority of patients (94%). This was done every other month. Plasma glucose (PG), serum cholesterol, triglyceride (TG), HDL cholesterol, creatinine, and uric acid were measured by standard methods using an autoanalyzer. HbA1C values were determined by high performance liquid chromatography. LDL cholesterol was calculated by Friedewald's formula using lipid levels obtained in blood samples taken after an overnight fasting. Complete blood cell count was analyzed using an automated blood cell counter.

Intrapersonal mean and coefficient of variation (CV) of HbA1c, fasting and postmeal plasma glucose (FPG and PMPG, resp.), and serum TG (FTG and PMTG, resp.) taken during the first 12 months after enrollment were calculated and their means [+ or -] SD were shown in Table 1; 153 patients (94%) had 6 measurements of LDL cholesterol, FPG, PMPG, FTG, and PMTG and 12 measurements of HbA1c and systolic BP.

Urinary albumin was measured once in random urine samples obtained during the first 3-4 months after enrollment using a turbidimetric immunoassay and expressed as albumin/creatinine ratio (ACR). Normoalbuminuria, microalbuminuria, and macroalbuminuria were defined as ACR < 30 mg/g, ACR between 30 and 299mg/g, and ACR [greater than or equal to] 300 mg/g, respectively [13]. Serum and urinary creatinine were measured enzymatically and estimated glomerular filtration rate (eGFR) was determined using the equation recommended by the Japanese Society for Nephrology [14]. CKD was diagnosed on 2 occasions: one at the entry and the other at the end of the observation time period. CKD was diagnosed using eGFR based on 2-4 measurements of serum creatinine obtained during 3-4 months on the 2 occasions. After the first visit in 2005 they were followed up for the subsequent 24 months and longer through December 31, 2012, with a median follow-up of 6.0 years (interquartile range: 4.1-6.5 years). Incident CKD was defined as eGFR < 60 mL/min/1.73 [m.sup.2] after 6.0 years in participants with an eGFR > 60 mL/min/1.73 [m.sup.2] at baseline. Linear regression was used to estimate changes in eGFR using a median of 52 creatinine measurements (interquartile range: 31-60) over 6.0 years of follow-up in each patient. Patients were staged according to the level of eGFR in mL/min/1.73 [m.sup.2]: G1: >90, G2: 60-89, G3a: 45-59, G3b: 30-44, and G4:15-29 [15].

IMT was measured by a well-trained medical technologist of Sadamitsu Hospital using ultrasonic diagnosis equipment (Shimadzu SDU-2200, Shimadzu, Tokyo, Japan) that was programmed with IMT software (Intimascope, Media Cross Co. Ltd., Tokyo, Japan) as previously described [16]. Carotid artery ultrasonography was performed using a 10MHz scanning frequency in B-mode with the participant in the supine position. Computer-based IMT was evaluated by two methods: maximum and average evaluations. Maximum evaluation was obtained by the IMT value at a maximal point of the region. Mean IMT is the average value of 250 computer-based points in the region. Mean values of the right and left maximum IMT and mean IMT were used for statistical analysis. The intraobserver CV for IMT measurements was 5.6 [+ or -] 0.8% and interobserver CV ranged from 2.5 to 10.9% with an average of 5.9% [16].

Data were presented as means [+ or -] SD unless otherwise stated. Differences between 2 groups were analyzed by i-test and frequencies of conditions by chi-square tests. Bivariate and multivariable Cox proportional hazards regression models were used for identifying associated factors of deterioration of CKD. Results were expressed as hazard ratio (HR) with their 95% confidence intervals (CI). A two-tailed p < 0.05 was considered statistically significant. All calculations were performed with SPSS system 15.0 (SPSS Inc., Chicago, IL).

3. Results

The baseline characteristics of 162 participants are shown in Table 1. Patients had relatively good glycemic, lipid, and BP control as previously reported [12]. Glucose-lowering therapy such as GLP-1 agonists, DPP4 inhibitors, and SGLT2 inhibitors is reported to improve renal function in type 2 diabetes patients. Among these drugs, however, a DPP4 inhibitor became available at the beginning of 2010 in Japan. There were only 6 patients who had been on the DPP4 inhibitor for the last 18 months of the study. Means of age and duration of diabetes in Tables 1 and 2 were those on study enrollment. Means of serum creatinine and eGFR were means of 2-4 measurements during the first 3-4 months after enrollment. ACR was measured once during the first 3-4 months after enrollment. Means of other variables were means of the intrapersonal mean values during the first 12 months after enrollment.

As compared to patients without CKD, those with CKD at baseline were older and had longer duration of diabetes and higher proportion of patients on BP-lowering agents (Table 1). Urinary ACR was higher in CKD patients. Although overt proteinuria was more prevalent in patients with than in those without CKD (15 versus 1%, p = 0.001) there was no difference in the proportion of patients with microalbuminuria (30 and 28% in patients with and without CKD, resp.). Consequently, patients with CKD tended to have higher proportion of ACR > 30 mg/g (Table 1). Diastolic BP was lower in CKD patients although the 2 groups did not differ in mean and CV of systolic BP. Fasting and postmeal TG were higher and HDL and LDL cholesterol were lower in patients compared to those without CKD although all differences were of borderline significance (p = 0.06). There was no difference in glycemic variables and carotid IMT between the 2 groups.

The level of eGFR decreased from 75.8[+ or -] 16.3 mL/min/1.73 [m.sup.2] at baseline to 67.4 [+ or -] 18.2 mL/min/1.73 [m.sup.2] after 6.0 years of follow-up (p < 0.01) with an annual decline of 1.11 [+ or -] 2.94 mL/min/1.73 [m.sup.2]. Proportion of patients with CKD (eGFR < 60 mL/min/1.73 [m.sup.2]) increased from 15.5% (n = 26) at baseline to 32.7% (n = 55) after follow-up whereas proportion of patients with stage G2 decreased from 63.6% (n = 107) to 54.7% (n = 92) and proportion with G1 decreased from 20.9% (n = 35) to 12.5% (n = 21).

Incident CKD (eGFR < 60 mL/min/1.73 [m.sup.2]) occurred in 32 patients. Progression from stage 3A to stage 3B and stage 4 occurred in 7 patients and 1 patient, respectively. In total deterioration of CKD occurred in 40 patients (Table 2). There were 3 patients whose CKD stage improved from G3A to G2 (eGFR: 60-75). They were included as nonprogressors. Patients compared with those without CKD deterioration were older and had higher uric acid levels. Baseline eGFR was lower while annual eGFR decline was higher in patients with CKD deterioration. Carotid maximum and mean IMT, urinary ACR, and leucocyte count also were higher in patients with CKD deterioration whereas the 2 groups did not differ in the proportion of patients with ACR [greater than or equal to] 30 mg/g. Although, among 162 patients, those on RAS inhibitors increased in number from 68 at baseline to 92 at the end of the study, the percentage of those patients increased at a similar rate both in progressors and in nonprogressors (from 40% to 60% and 43% to 56%, resp.).

Cox proportional hazard regression models were used for identifying associated factors of deterioration of CKD (Table 3). Independent variables included were 6 variables that showed significant associations with CKD progression in Table 1. Mean and CV of HbA1c were also included because they showed significant associations with CKD progression in bivariate model (HR: 1.5, 95% CI: 1.1-2.0, and p = 0.006 and HR: 1.09, 95% CI: 1.09-1.13, and p < 0.001, resp.). Maximum IMT and CV HbA1c were significant predictors of CKD deterioration. Leucocyte count and baseline eGFR were associated with CKD deterioration, but the relations were of borderline significance. In a model which included mean IMT instead of maximum IMT, CV-HbA1c (HR: 1.12, 95% CI: 1.04-1.21, and p = 0.004), mean IMT (HR: 7.8, 95% CI: 0.8-76, and p = 0.08), baseline eGFR (HR: 0.97, 95% CI: 0.94-1.002, and p = 0.07), and leucocyte count (HR: 1.29,95% CI: 0.97-1.71, and p = 0.08) were independent predictors of CKD deterioration.

4. Discussion

This study demonstrates in type 2 diabetic patients with preserved kidney function and relatively good glycemic, lipid, and BP control at baseline that the presence of CVD measured as subclinical carotid atherosclerosis was a predictor for deterioration of CKD. In addition, a nontraditional risk factor, namely, visit-to-visit variation in HbA1c, was found to be a risk factor of CKD deterioration.

Cross-sectional associations between reduced kidney function and IMT thickening are reported in patients with type 2 diabetes [17,18], hypertension [19], and CKD [20, 21] and in outpatients [22]. Prospective studies have shown a positive correlation between increased carotid IMT and the risk for kidney function decline and incident CKD in the elderly and the general population [9-11]. Recently, carotid IMT has been reported to be associated with end-stage renal disease in the general population [23]. The current study is the first, to our knowledge, to report that subclinical carotid atherosclerosis is an independent predictor of future deterioration of CKD in type 2 diabetic patients with preserved kidney function. These findings suggest the shared etiology of atherosclerosis and progression of kidney function.

Long-term glycemic variability has been suspected to be a major factor of diabetic complications [24]. We have recently shown a direct association between visit-to-visit HbA1c variability and an annual decline in eGFR of patients with type 2 diabetes [12]. In the present study, the association between visit-to-visit HbA1c variability and the progression of CKD was confirmed. Several reasons may be involved in the association between visit-to-visit HbA1c variability and outcomes as suggested by Ceriello and Kilpatrick [25]. They include "metabolic memory" phenomenon [26]. They may be related to the fact that microvascular complication risk rises exponentially, rather than linearly, as HbA1c rises. It is also possible that patient with HbA1c variability are those in whom the rest of their diabetes management is suboptimal.

There were no differences in BP between patients whose kidney function deteriorated and those whose kidney function did not in the present study. This may be in line with observation that BP control of 138/86 or 132/78 mmHg appeared to stabilize renal function in hypertensive type 2 diabetic patients without overt albuminuria over a 5year period [27], as progressors and nonprogressors in the present study had BP control of 131/72 and 128/72 mmHg, respectively.

The strength of the current study is that mean and CV of HbA1c and other traditional and nontraditional risk factors shown in Table 1 were calculated from 6-12 measurements in 94% of participants. In addition, the diagnosis of CKD was based on 2-4 creatinine measurements not only at entry but also at the end of the observation. Therefore, participants who met the criteria did so for a period of at least 3 months. As previously described in detail [12], serum creatinine and hence eGFR during follow-up period were much more frequently measured. This could contribute to the reliability of changes in kidney function. Major limitations are that study participants were small in number and from a single clinic in Japan. However, the characteristics of our study participants are similar to those reported in a previous large-scale study in Japan [28]. We used eGFR rather than more precise measures of kidney function, like iothalamate clearance. In addition, this cohort of participants consisted of Japanese only, which limits generalizability. Finally, the sample size and the number of CKD related incidents occurred in the present study seem to be small to lead a robust conclusion although statistical power was not calculated.

5. Conclusions

Measurements of carotid IMT and visit-to-visit HbA1c variability retain predictive power with respect to CKD progression even after traditional and nontraditional risk factors for kidney disease progression have been taken into consideration. These results suggest that type 2 diabetic patients with subclinical carotid atherosclerosis should be recognized as a group at high risk for CKD progression. In addition, these findings also raise the issue of whether aggressive treatment of traditional risk factors for subclinical carotid atherosclerosis might, in fact, decrease progression to renal replacement therapy. Further studies are needed to confirm the association in other ethnic groups with more patients.

http://dx.doi.org/10.1155/2016/3295747

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are indebted to all the participants for their dedicated and conscientious collaboration. They also thank Mr. Ken-ichi Sakamoto, Sadamitsu Hospital, for measurement of carotid IMT, Dr. Takeo Sadamitsu, Ms. Ayako Kameyama, and Ms. Atsuko Muranaka, Sadamitsu Hospital, Mayu Terazawa-Watanabe, for their help.

References

[1] G. Manjunath, H. Tighiouart, H. Ibrahim et al., "Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community," Journal of the American College of Cardiology, vol. 41, no. 1, pp. 47-55, 2003.

[2] D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, "Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization," Archives of Internal Medicine, vol. 164, no. 6, pp. 659-663, 2004.

[3] C. S. Fox, M. G. Larson, E. P. Leip, B. Culleton, P. W. F. Wilson, and D. Levy, "Predictors of new-onset kidney disease in a community-based population," Journal of the American Medical Association, vol. 291, no. 7, pp. 844-850, 2004.

[4] H. Ueda, E. Ishimura, T. Shoji et al., "Factors affecting progression of renal failure in patients with type 2 diabetes," Diabetes Care, vol. 26, no. 5, pp. 1530-1534, 2003.

[5] A. J. Bleyer, L. R. Shemanski, G. L. Burke, K. J. Hansen, and R. G. Appel, "Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population," Kidney International, vol. 57, no. 5, pp. 2072-2079, 2000.

[6] P. Muntner, J. Coresh, J. C. Smith, J. Eckfeldt, and M. J. Klag, "Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study," Kidney International, vol. 58, no. 1, pp. 293-301, 2000.

[7] J.-M. Halimi, B. Giraudeau, S. Vol et al., "Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population," Kidney International, vol. 58, no. 3, pp. 1285-1292, 2000.

[8] L. Fried, C. Solomon, M. Shlipak et al., "Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals," Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3184-3191, 2004.

[9] M. G. Shlipak, R. Katz, B. Kestenbaum, L. F. Fried, D. Siscovick, and M. J. Sarnak, "Clinical and subclinical cardiovascular disease and kidney function decline in the elderly," Atherosclerosis, vol. 204, no. 1, pp. 298-303, 2009.

[10] M. Chonchol, H. Gnahn, and D. Sander, "Impact of subclinical carotid atherosclerosis on incident chronic kidney disease in the elderly," Nephrology Dialysis Transplantation, vol. 23, no. 8, pp. 2593-2598, 2008.

[11] M. Shimizu, N. Furusyo, F. Mitsumoto et al., "Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS)," Atherosclerosis, vol. 238, no. 2, pp. 207-212, 2015.

[12] A. Takenouchi, A. Tsuboi, M. Terazawa-Watanabe, M. Kurata, K. Fukuo, and T. Kazumi, "Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes," Journal of Diabetes and Metabolic Disorders, vol. 14, no. 1, article no. 69, 2015.

[13] American Diabetes Association, "(9) Microvascular complications and foot care," Diabetes Care, vol. 38, supplement 1, pp. S58-S60, 2015.

[14] S. Matsuo, E. Imai, M. Horio et al., "Revised equations for estimated GFR from serum creatinine in Japan," American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982-992, 2009.

[15] A. S. Levey, P. E. De Jong, J. Coresh et al., "The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report," Kidney International, vol. 80, no. 1, pp. 17-28, 2011.

[16] T. Yanase, S. Nasu, Y. Mukuta et al., "Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope," American Journal of Hypertension, vol. 19, no. 12, pp. 1206-1212, 2006.

[17] H. Ito, Y. Komatsu, M. Mifune et al., "The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: A Cross-Sectional Study," Cardiovascular Diabetology, vol. 9, article 18, 2010.

[18] B. Lu, J. Wan, Y. Yang, Y. Li, and R. Hu, "The estimated glomerular filtration rate is associated with subclinical atherosclerosis, independently of albuminuria, in patients with type 2 diabetes," International Angiology, vol. 32, no. 5, pp. 532-539, 2013.

[19] N. Ishikaza, Y. Ishizaka, E.-I. Toda et al., "Association between chronic kidney disease and carotid intima-media thickening in individuals with hypertension and impaired glucose metabolism," Hypertension Research, vol. 30, pp. 1035-1041, 2007.

[20] L. Zhang, F. Zhao, Y. Yang et al., "Association between carotid artery intima-media thickness and early-stage CKD in a Chinese population," American Journal of Kidney Diseases, vol. 49, no. 6, pp. 786-792, 2007.

[21] E. Preston, M. R. Ellis, E. Kulinskaya, A. H. Davies, and E. A. Brown, "Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD," American Journal of Kidney Diseases, vol. 46, no. 5, pp. 856-862, 2005.

[22] R. Kawamoto, N. Ohtsuka, T. Kusunoki, and N. Yorimitsu, "An association between the estimated glomerular filtration rate and carotid atherosclerosis," Internal Medicine, vol. 47, no. 5, pp. 391398, 2008.

[23] Y. Pang, Y. Sang, S. H. Ballew et al., "Carotid intima-media thickness and incident ESRD: The Atherosclerosis Risk in Communities (ARIC) study," Clinical Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1197-1205, 2016.

[24] C. Gorst, C. S. Kwok, S. Aslam et al., "Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis," Diabetes Care, vol. 38, no. 12, pp. 2354-2369, 2015.

[25] A. Ceriello and E. S. Kilpatrick, "Glycemic variability: both sides of the story," Diabetes Care, vol. 36, Supplement 2, pp. S272-S275, 2013.

[26] M. A. Reddy, E. Zhang, and R. Natarajan, "Epigenetic mechanisms in diabetic complications and metabolic memory," Diabetologia, vol. 58, no. 3, pp. 443-455, 2015.

[27] R. O. Estacio, B. W. Jeffers, N. Gifford, and R. W. Schrier, "Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes," Diabetes Care, vol. 23, supplement 2, pp. B54-B64, 2000.

[28] H. Sone, S. Tanaka, S. Iimuro et al., "Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)," Diabetologia, vol. 53, no. 3, pp. 419-428, 2010.

Akiko Takenouchi, (1) Ayaka Tsuboi, (2,3) Miki Kurata, (1,2) Keisuke Fukuo, (1,2) Tsutomu Kazumi (2,4)

(1) Department of Food Sciences and Nutrition, School of Human Environmental Sciences, Hyogo, Japan

(2) Research Institute for Nutrition Sciences, Mukogawa Women's University, Hyogo, Japan

(3) Department of Nutrition, Osaka City Juso Hospital, Osaka, Japan

(4) Diabetes Division, Sadamitsu Hospital, Hyogo, Japan

Correspondence should be addressed to Tsutomu Kazumi; kazumi@mukogawa-u.ac.jp

Received 20 August 2016; Revised 25 October 2016; Accepted 28 November 2016

Academic Editor: Daisuke Yabe
Table 1: Baseline characteristics of 162 patients with type 2 diabetes
who had and did not have chronic kidney disease at baseline.

                               Overall              Chronic kidney
                                                    disease at
                                                    baseline

                               (n = 162)            Present (n = 25)

Male sex (n, %)                89, 55               12,48
Smokers (n, %)                 53, 33               6, 24
Age (years)                    62 [+ or -] 10       69 [+ or -] 9
BMI (kg/[m.sup.2])             24.2 [+ or -] 3.7    25.3 [+ or -] 4.0
Waist circumference (cm)       87.0 [+ or -] 10.0   88.8 [+ or -] 7.7
Duration of diabetes (years)   9.7 [+ or -] 7.2     12.8 [+ or -] 8.0
Treatment of diabetes;         53/81/28, 33/50/17   4/14/7, 16/56/28
diet/OHA/insulin (n, %)
Hypertension; CCB/RASi/        56/68/7, 35/42/4     18/17/5, 72/68/20
diuretics (n, %)
HbA1c (%)                      7.0 [+ or -] 0.8     7.2 [+ or -] 0.8
Fasting PG (mg/dL)             125 [+ or -] 23      125 [+ or -] 24
Postbreakfast PG (mg/dL)       154 [+ or -] 48      162 [+ or -] 51
CV-HbA1c (%)                   6.7 [+ or -] 5.7     6.8 [+ or -] 4.5
Total cholesterol (mg/dL)      188 [+ or -] 21      178 [+ or -] 26
LDL cholesterol (mg/dL)        112 [+ or -] 22      104 [+ or -] 24
HDL cholesterol (mg/dL)        55 [+ or -] 15       50 [+ or -] 12
Fasting TG (mg/dL)             114 [+ or -] 51      132 [+ or -] 73
Postbreakfast TG (mg/dL)       145 [+ or -] 62      167 [+ or -] 80
Serum creatinine (mg/dL)       0.8 [+ or -] 0.2     1.0 [+ or -] 0.3
eGFR (mL/min/1.73 [m.sup.2])   76 [+ or -] 16       51 [+ or -] 9
AeGFR (mL/min/1.73             -1.1 [+ or -] 2.9    -1.2 [+ or -] 2.4
[m.sup.2]/year)
Uric acid (mg/dL)              5.2 [+ or -] 1.3     5.7 [+ or -] 1.3
Systolic BP (mmHg)             128 [+ or -] 12      131 [+ or -] 12
CV-systolic BP (%)             8.1 [+ or -] 2.2     8.4 [+ or -] 2.1
Diastolic BP (mmHg)            72 [+ or -] 6        69 [+ or -] 5
Urinary ACR (mg/g)             86 [+ or -] 327      233 [+ or -] 531
log ACR                        1.3 [+ or -] 0.6     1.7 [+ or -] 0.8
Leucocyte count                5.8 [+ or -] 1.5     6.1 [+ or -] 1.3
([10.sup.3]/[micro]L)
Maximum IMT (mm)               1.0 [+ or -] 0.3     1.1 [+ or -] 0.4
Mean IMT (mm)                  0.8 [+ or -] 0.2     0.9 [+ or -] 0.2
ACR [greater than or equal     53,33                12, 48
to] 30 mg/g (n, %)

                               Chronic kidney       p values
                               disease at
                               baseline

                               Absent (n = 137)

Male sex (n, %)                77,56                0.45
Smokers (n, %)                 47, 3                0.30
Age (years)                    61 [+ or -] 10       0.000
BMI (kg/[m.sup.2])             24.0 [+ or -] 3.6    0.10
Waist circumference (cm)       86.7 [+ or -] 10.3   0.35
Duration of diabetes (years)   9.1 [+ or -] 7.0     0.02
Treatment of diabetes;         49/67/21, 36/49/15   0.10
diet/OHA/insulin (n, %)
Hypertension; CCB/RASi/        38/51/2, 28/37/1     0.000
diuretics (n, %)
HbA1c (%)                      7.0 [+ or -] 0.9     0.25
Fasting PG (mg/dL)             126 [+ or -] 22      0.86
Postbreakfast PG (mg/dL)       152 [+ or -] 48      0.37
CV-HbA1c (%)                   6.7 [+ or -] 5.9     0.96
Total cholesterol (mg/dL)      190 [+ or -] 20      0.012
LDL cholesterol (mg/dL)        113 [+ or -] 22      0.06
HDL cholesterol (mg/dL)        56 [+ or -] 16       0.06
Fasting TG (mg/dL)             111 [+ or -] 45      0.06
Postbreakfast TG (mg/dL)       141 [+ or -] 57      0.06
Serum creatinine (mg/dL)       0.7 [+ or -] 0.1     0.000
eGFR (mL/min/1.73 [m.sup.2])   80 [+ or -] 13       0.000
AeGFR (mL/min/1.73             -1.1 [+ or -] 3.0    0.93
[m.sup.2]/year)
Uric acid (mg/dL)              5.1 [+ or -] 1.2     0.03
Systolic BP (mmHg)             128 [+ or -] 12      0.20
CV-systolic BP (%)             8.0 [+ or -] 2.2     0.41
Diastolic BP (mmHg)            73 [+ or -] 7        0.02
Urinary ACR (mg/g)             59 [+ or -] 268      0.014
log ACR                        1.2 [+ or -] 0.5     0.001
Leucocyte count                5.7 [+ or -] 1.5     0.19
([10.sup.3]/[micro]L)
Maximum IMT (mm)               1.0 [+ or -] 0.3     0.14
Mean IMT (mm)                  0.8 [+ or -] 0.2     0.26
ACR [greater than or equal     41,30                0.08
to] 30 mg/g (n, %)

Mean [+ or -] SD or n, %. OHA; oral hypoglycemic agents, CCB; calcium
channel blockers, RASi; renin-angiotensin system inhibitors, PG;
plasma glucose, CV; coefficient of variation, eGFR; estimated
glomerular filtration rate, AeGFR; annual changes in eGFR, BP; blood
pressure, ACR; albumin/creatinine ratio, IMT; intima-media thickness,
* p < 0.05, ** p < 0.01, and *** p < 0.001.

Table 2: Baseline clinical and biochemical characteristics of 162 type
2 diabetic patients whose kidney function deteriorated and did not
deteriorate over a 6.0-year follow-up.

                      Deterioration
                                                                p
                      Present(n = 40)     Absent (n = 122)     values

Male sex (n, %)       21,53               68,56                0.72
Smokers (n, %)        14, 35              39, 32               0.75
Age (years)           66 [+ or -] 10      61 [+ or -] 10       0.01
BMI (kg/[m.sup.2])    24.6 [+ or -] 3.1   24.1 [+ or -] 3.9    0.52
Waist circumference   87.9 [+ or -] 7.8   86.7 [+ or -] 10.6   0.52
(cm)
Duration of           10.6 [+ or -] 8.1   9.4 [+ or -] 7.0     0.35
diabetes (years)
Treatment of          12/21/7, 30/53/18   41/60/21, 34/49/17   0.91
diabetes; diet/OHA/
insulin (n, %)
Hypertension; CCB/    17/16/3, 43/40/8    39/52/4, 32/43/3     0.41
RASi/diuretics (n,
%)
HbA1c (%)             7.1 [+ or -] 0.8    7.0 [+ or -] 0.9     0.42
Fasting PG (mg/dL)    125 [+ or -] 22     125 [+ or -] 23      0.97
Postbreakfast PG      155 [+ or -] 44     154 [+ or -] 50      0.87
(mg/dL)
CV-HbA1c (%)          7.9 [+ or -] 5.7    6.4 [+ or -] 5.7     0.15
Total cholesterol     188 [+ or -] 21     188 [+ or -] 21      0.998
(mg/dL)
LDL cholesterol       112 [+ or -] 22     111 [+ or -] 22      0.92
(mg/dL)
HDL cholesterol       53 [+ or -] 14      56 [+ or -] 16       0.28
(mg/dL)
Fasting TG (mg/dL)    127 [+ or -] 55     110 [+ or -] 49      0.06
Postbreakfast TG      158 [+ or -] 70     141 [+ or -] 59      0.17
(mg/dL)
Serum creatinine      0.8 [+ or -] 0.2    0.7 [+ or -] 0.2     0.07
(mg/dL)
eGFR (mL/min/1.73     69 [+ or -] 14      78 [+ or -] 17       0.004
[m.sup.2])
AeGFR (mL/min/1.73    -3.1 [+ or -] 2.9   -0.5 [+ or -] 2.7    0.000
[m.sup.2]/year)
Uric acid (mg/dL)     5.6 [+ or -] 1.5    5.1 [+ or -] 1.2     0.048
Systolic BP (mmHg)    131 [+ or -] 10     128 [+ or -] 12      0.17
CV-systolic BP (%)    8.1 [+ or -] 2.3    8.0 [+ or -] 2.2     0.82
Diastolic BP (mmHg)   72 [+ or -] 6       72 [+ or -] 7        0.85
Urinary ACR (mg/g)    223 [+ or -] 624    41 [+ or -] 89       0.002
log ACR               1.5 [+ or -] 0.6    1.2 [+ or -] 0.5     0.013
Leucocyte count       6.2 [+ or -] 1.4    5.7 [+ or -] 1.5     0.046
([10.sup.3]/
[micro]L)
Maximum IMT (mm)      1.1 [+ or -] 0.3    1.0 [+ or -] 0.3     0.03
Mean IMT (mm)         0.9 [+ or -] 0.2    0.8 [+ or -] 0.2     0.02
ACR [greater than or e17,43               36,30                0.13

Mean [+ or -] SD or n, %. Abbreviations are the same as in Table 1.

Table 3: Cox regression analyses for exacerbation of chronic kidney
disease in patients with type 2 diabetes and preserved kidney
function.

Independent variables   HR      95% CI        p values

Age                     1.032   0.976-1.091   0.27
HbA1c                   1.256   0.732-2.154   0.41
CV-HbA1c                1.121   1.040-1.208   0.003
log ACR                 1.800   0.838-3.868   0.13
Maximum IMT             4.020   1.135-14.24   0.03
eGFR                    0.971   0.942-1.001   0.06
Uric acid               1.124   0.798-1.582   0.50
Leucocyte count         1.304   0.979-1.737   0.07

HR: hazard ratio. CI: confidence interval. Other abbreviations are the
same as in Table 1.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Takenouchi, Akiko; Tsuboi, Ayaka; Kurata, Miki; Fukuo, Keisuke; Kazumi, Tsutomu
Publication:Journal of Diabetes Research
Article Type:Report
Date:Jan 1, 2017
Words:5126
Previous Article:Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Next Article:Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |